Restenosis prevention heart trial begins:
This article was originally published in Clinica
Novoste has begun enrolling patients for a 1,100-patient trial of its Beta-Cath intracoronary beta radiation therapy device: not completed recruitment as reported in Clinica no 766, p 15. The Beta-Cath system is intended to lower the incidence of coronary restenosis, reducing the need for ongoing coronary interventions.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.